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NeoepitopeProteoglycans are key components of extracellular matrices, providing structural support as well as inﬂuenc-
ing cellular behaviour in physiological and pathological processes. The diversity of proteoglycan function
reported in the literature is equally matched by diversity in proteoglycan structure. Members of the ADAMTS
(A Disintegrin And Metalloproteinase with ThromboSpondin motifs) family of enzymes degrade proteogly-
cans and thereby have the potential to alter tissue architecture and regulate cellular function. In this review,
we focus on ADAMTS enzymes that degrade the lectican and small leucine-rich repeat families of proteogly-
cans. We discuss the known ADAMTS cleavage sites and the consequences of cleavage at these sites. We illus-
trate our discussion with examples from the literature in which ADAMTS proteolysis of proteoglycans makes
profound changes to tissue function.oteinase with ThromboSpondin
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Cells in all tissues are surrounded by extracellular matrix (ECM). As
well as a scaffold providing structural support, the ECM has an active
role in regulating the activity and behaviour of cells, including cell
shape, survival, differentiation, movement, proliferation and in some
cases, cell death. These cellular activities and behaviours are mediated
by specialised ECM proteins and glycoproteins, for example, proteogly-
cans with their highly charged glycosaminoglycan side chains, as well
as ﬁbril- and network-formingmolecules such as collagen, elastin, lam-
inin and ﬁbronectin. Many physiological processes such asmorphogen-
esis, ovulation, parturition andwound healing require closely regulated
degradation of the ECM, whereas in other cases matrix degradation
leads to pathology. Proteoglycans are key components of extracellular
matrices and have been recognised as such for many decades. In
contrast, the family of ADAMTS (A Disintegrin And Metalloproteinase
with ThromboSpondinmotifs) proteinaseswas only recently discovered[1]. Since then several ADAMTS enzymes, including ADAMTS-5
and ADAMTS-13, have made a big splash in the literature with the dis-
covery that their proteolytic actions have key roles in arthritis and
blood-clotting diseases, respectively. Here we will review the proteoly-
sis of proteoglycans by ADAMTS enzymes, focussing particularly on
the consequences of these proteolytic events.
Proteoglycans are present in the ECM of almost all eukaryotes and
have a diverse range of functions that inﬂuence both the physical and
biomolecular properties of tissues. Many proteoglycans have modular
domain structures with interaction sites that allow them to form
molecular bridges between cells and matrix. Other proteoglycans in-
ﬂuence extracellular architecture by regulating collagen ﬁbrillogen-
esis. Cell surface and extracellular proteoglycans that bind growth
factors can act as co-receptors for signalling, or depots for sequestra-
tion. Accordingly, proteolysis of proteoglycans by ADAMTS enzymes
can have detrimental effects, creating matrices with disrupted cell-
matrix communication, matrices with impaired ﬁbrillar networks, or
matrices with altered biomechanical properties. In other situations,
proteolysis of proteoglycans by ADAMTS enzymes is critical for
normal physiological processes. Given the large number and diversity
of proteoglycans, this review is necessarily restricted to only two sub-
families of proteoglycans: the lecticans, including aggrecan, versican,
brevican and neurocan; and the small leucine-rich repeat proteogly-
cans, or SLRPs (reviewed in [2–7]).
2. The ADAMTS family of proteinases
The ADAMTS family belongs to the metzincin superfamily of
metalloendopeptidases and now numbers 19 members, including en-
zymes with broad catalytic activities against a range of substrates. The
1617H. Stanton et al. / Biochimica et Biophysica Acta 1812 (2011) 1616–1629ADAMTS enzymes are secreted proteinases, and accordingly, the
known ADAMTS substrates are extracellular also. It is likely that
other substrates are yet to be discovered.2.1. Domain structure and conserved motifs
All ADAMTS enzymes share a common domain organisation com-
prising, from the N-terminus, a signal peptide, a pro-domain, a catalytic
domain, a disintegrin-like domain, a central thrombospondin (TS)
repeat, a cysteine-rich and a spacer domain. With the exception of
ADAMTS-4, all other ADAMTS enzymes have further TS repeats and sev-
eral familymembers have additional, uniquemodules at the C-terminus
(Fig. 1). There are several, excellent reviews on ADAMTS domain orga-
nisation and function [8–12].
The pro-domain is generally considered to be essential for proper
folding of the metzincins. It is also credited with maintaining enzyme
latency, by virtue of its proximity to the catalytic pocket, where it
impedes substrate access and hydrolysis. Excision of the ADAMTS
propeptide is typically a prerequisite for ADAMTS activity; however
there is no evidence for the cysteine switch mechanism that has
been so well described for MMP activation. Rather, every ADAMTS
enzyme has at least one consensus motif recognised by proprotein
convertases (such as furin or furin-like enzymes) and it is likely that
convertase processing is common to all ADAMTS enzymes.
The catalytic domain of the ADAMTS family members has the
highest degree of sequence homology. ADAMTS enzymes have in
common with other clan members the active-site consensus se-
quence HEBxHxBGBxH, in which the three histidines coordinate a
zinc ion essential for hydrolysis and where B represents bulky apolar
residues. A short distance C-terminal to the third histidine is a highlyFig. 1. The domain structure and phylogenetic analysis of the ADAMTSconserved methionine that constitutes the ‘Met-turn’, a tight turn
common to the catalytic domain of all metzincins (reviewed in [13]).
The ancillary domains C-terminal to the catalytic domain show
less sequence homology. The disintegrin-like domain was named for
its sequence similarity to snake venom disintegrins, but there is no
evidence to date that it binds integrins. Crystal structures of
ADAMTS-1, -4 and -5 show that the disintegrin-like domain lies adja-
cent, and in close proximity to the active site, implying that it func-
tions to regulate activity, perhaps by providing an auxiliary
substrate-binding surface [14,15]. The remaining ancillary domains
have roles in substrate recognition andmatrix localisation. C-terminal
to the disintegrin domain is a central TS repeat that is highly con-
served and shows sequence homology to thrombospondins 1 and 2.
Conserved amino acid residues include the CSR(T/S)C pentapeptide
and several glycine, tryptophan and proline residues [16]. Further
towards the C-terminus is a cysteine-rich domain containing 10
well conserved cysteine residues.
Following the cysteine-rich domain is a cysteine-free spacer do-
main of variable length. The spacer is the least homologous of the
ADAMTS domains. With the exception of ADAMTS-4, between one
and fourteen further TS repeats follow immediately C-terminal to
the spacer domain, often in combination with other modules includ-
ing a mucin module in ADAMTS-7 and -12, a GON-1 module in
ADAMTS-9 and -20, two CUB-like domains in ADAMTS-13 or protease
and lacunin (PLAC) domains in more than half the family (reviewed
in [8–12]). The sequence of the C-terminal TS modules is more vari-
able than the central thrombospondin module, but their function ap-
pears also to be matrix binding.
Fig. 1 shows the domain structure and phylogenetic analysis of the
ADAMTS familymembers, based on full length protein sequence analysis
[8,12]. The proteoglycan-degrading enzymes, ADAMTS-1, -4, -5, -8 andfamily. Adapted from [8,11]. Note that domains are not to scale.
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are ADAMTS-9 and -20, having an additional GON-1 domain at their
C-terminus.
2.2. Structural features determining catalytic activity, inhibition,
substrate recognition and tissue localisation
2.2.1. The propeptide
Proprotein convertases (PCs) cleave ADAMTS enzymes at the con-
sensus motif R/KXnR/K↓, where n=0, 2, 4 or 6 and X is any amino
acid. Of the nine mammalian PCs, seven recognise this motif (PC1/3,
PC2, furin, PC4, PC5/6A/B, PACE4 and PC7) and their activities parti-
tion to different cellular compartments, (reviewed in [17]). The PCs
furin and PC7 are membrane-bound PCs that are active in the trans-
Golgi network and shuttle to the cell surface and back via endosomes.
Furin has also been shown to operate extracellularly, in a shed, solu-
ble form. Other PCs are found in dense core granules and/or constitu-
tively secreted, allowing them to operate extracellularly [18]. The
advantage of a system that targets zymogen processing to multiple
locations is that speciﬁc ADAMTS enzymes can be maximally active
at a precise location, perhaps co-localised with a preferred substrate.
Furin is the archetypal and best studied of the PCs, and many of
the studies examining ADAMTS processing have been done in cell
lines, using furin inhibitors, transfection of furin constructs or furin
siRNA. ADAMTS-1 and -4 can be activated by furin in vitro, in the
trans-Golgi network [19,20], whereas ADAMTS-5 activation by furin
is thought to be an extracellular event [21]. PACE4 and PC5/6 can ac-
tivate recombinant ADAMTS-4 in a cell-free assay [22] and co-trans-
fection studies show that PC7 can process ADAMTS-5 (16). Malfait
and co-authors have shown that the majority of PC activity extracted
from human osteoarthritic cartilage is PACE4 and that PACE4 can ac-
tivate both ADAMTS-4 and -5 in cartilage, in situ [23]. The authors
ruled out a role for furin in this system.
Conventionwould dictate that the pro-domain of ADAMTS enzymes
must be removed to allow substrate access to the catalytic pocket, prior
to hydrolysis. Certainly, removal of the pro-domain by a PC is vital for
ADAMTS-4 [22] and -5 [21] activity against aggrecan, or aggrecan and
versican respectively. Surprisingly, some ADAMTS enzymes are active
with an intact pro-domain. For example, ADAMTS-13, which has a rela-
tively short pro-domain, cleaves vonWillebrand factor with its pro-do-
main intact [24] and ADAMTS-7 can cleave alpha-2-macroglobulin [25],
also with an intact prodomain. ADAMTS-9 further tests convention be-
cause propeptide excision acts to reduce is its catalytic activity [26].
Although the variable nature of ADAMTS activation presents a challenge
to investigators, it may be a boon for ADAMTS inhibitor design, if indi-
vidual convertases can be targeted for inhibition, and the cellular loca-
tion at which activation takes place can be exploited.
2.2.2. The active site
Crystal structures have been solved for truncated ADAMTS-1, -4
and -5 enzymes bound to an inhibitor [14,15,27]. Several features of
the catalytic domain distinguish ADAMTS enzymes from other met-
zincins. The ADAMTS enzymes have a unique calcium binding cluster
in the catalytic domain that is essential for structural integrity [27].
Also unique to ADAMTS-4 and -5 is the potential for the active site
to assume two different conformations, an active ‘open’ form and an
inactive ‘closed’ form [15]. The authors propose that these forms
might exist in equilibrium; this dynamic state sets the ADAMTS en-
zymes apart from other metzincins. One interesting feature of the
ADAMTS catalytic domain is its close association with the disintegrin
domain which forms part of the substrate binding pocket in the active
site cleft [28]. Most promising for ADAMTS enzymes with roles in
pathology, is that the ADAMTS active site pocket is sufﬁciently differ-
ent from its counterpart in the MMP and ADAM families to facilitate
design of ADAMTS-speciﬁc inhibitors. Although inhibitors selective
for ADAMTS subgroups should be achievable by exploiting differencesin key residues in the active site [12], the design of active site inhibi-
tors that can distinguish between ADAMTS-4 and ADAMTS-5 could be
problematic since their active sites are well conserved and their
structural topography is virtually identical [15].
2.2.3. Ancillary domains
The many and varied modules of the ADAMTS ancillary domains
regulate ADAMTS activity, inhibition, tissue localisation and substrate
speciﬁcity. Focussing ﬁrst on activity, studies with domain deletion
mutants have shown that removal of C-terminal ancillary domains
of ADAMTS-1, -4, -5, -8, and -9 greatly reduces their activity against
natural substrates [29–34]. For ADAMTS-4 and -5, isolated catalytic
domains are inactive against native aggrecan [29]. The minimum do-
main composition permitting aggrecanolysis is the catalytic domain,
the disintegrin domain and the ﬁrst TS1 repeat [29,31,35]. The TS re-
peats are also involved in binding to the naturally-occurring ADAMTS
inhibitor, TIMP-3, which inhibits ADAMTS-1 [36] and is a potent in-
hibitor of ADAMTS-4 and -5 [37–39].
The cysteine-rich and spacer domains of ADAMTS-1, -4, and -5 de-
termine binding to sulphated glycosaminoglycans and tissue localisa-
tion [29–31,35,40–42]. The spacer domain of ADAMTS-4 interacts
with cell surface and pericellular proteoglycans [42], localising the
activity of full length ADAMTS-4 close to the chondrocytes. Similarly,
ADAMTS-5 activity is located at the cell surface and the ECM via inter-
actions between the cysteine-rich domain and sulphated glycosami-
noglycans [29] and/or hyaluronan (HA) [43]. Post-translational
processing of the ADAMTS C-terminus is common amongst the
ADAMTS enzymes [31,34,42,44–46] and can be autolytic [35,40,42].
3. Extracellular proteoglycans: diverse structure and function
Although proteoglycans can be classiﬁed into loose sub-groupings
based on regions of primary sequence homology, collectively, proteo-
glycan core proteins are diverse and unrelated in their structure and
function. Instead, the single unifying feature of proteoglycans is the
presence of one or more glycosaminoglycan chains, covalently at-
tached to the core protein. By this criterion, molecules from many
and varied phylogenetic groupings qualify as proteoglycans. For
example, type IX collagen with a 70% incidence of a single CS glycos-
aminoglycan substitution in the α2(IX) chain [47] can be considered
a part-time proteoglycan, and ADAMTS-7 with a CS chain substituted
in its mucin domain [25] is also a proteoglycan.
Glycosaminoglycans are linear carbohydrate chains comprising re-
peating disaccharide units carrying negatively-charged sulphate and car-
boxylate groups (Fig. 2). The chains may be chondroitin sulphate (CS),
dermatan sulphate (DS), keratan sulphate (KS), heparan sulphate (HS)
or heparin, with multiple disaccharide combinations possible for each
chain type. Some proteoglycans have two or even three different chain
types attached to a single core protein. For example, aggrecan is substitut-
ed with CS and KS chains (Fig. 3), the cell surface HA receptor CD44 can
carry CS and/or HS chains [48] and perlecan can carry CS, HS and KS
chains [49]. Many other proteoglycans can have different glycosamino-
glycan chain types attached, depending on the tissue type, stage of de-
velopment, maturation or disease state [48,50,51]. Superimposed on
these variations in chain type, is themore subtle variation in the pattern
of sulphation within a single species of glycosaminoglycan chain on a
common core protein. For example, the ratio of chondroitin-4-
sulphate to chondroitin-6-sulphate on aggrecan in human knee carti-
lage changes markedly with age, topographical position, zone of carti-
lage and tissue composition [52]. In humans, the amount of KS on the
lectican, aggrecan (see below) increases from a minimal percentage at
birth to over a quarter of the glycosaminoglycan content at maturity
[53] and compared with aggrecan from immature cartilage, aggrecan
from adult cartilage is also substantiallymore sulphated andmore high-
ly modiﬁed by fucosylation and sialylation. Clearly, there is inﬁnite
scope for heterogeneity in glycosaminoglycan and proteoglycan
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Fig. 2. The repeating disaccharide structure of glycosaminoglycans. Hyaluronan is synthesised without a covalent link to any protein. DS is formed from CS by intracellular epimer-
isation of glucuronate (GlcA) to iduronate (IdoA). 2-sulphated hexuronate residues are more common in DS than CS. Heparin is a more extensively epimerized and sulphated form
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erogeneity are developing rapidly, however understanding the func-
tional consequences of a seemingly boundless range of heterogeneity
within proteoglycans is an ongoing challenge. Excellent reviews of pro-
teoglycan structure and function can be found elsewhere [4,5,7,54,55].
Finally, it is perhaps not surprising to ﬁnd examples of ADAMTS
activity being directly inﬂuenced by the presence or absence of gly-
cosaminoglycans. For example, compared with fully glycosylated
aggrecan, deglycosylated aggrecan is a poor substrate for ADAMTS-4
and -5 [29,31,56,57]. The sites of interaction between aggrecan's gly-
cosaminoglycans, and ADAMTS-4 and -5, have been mapped to the
spacer domain of ADAMTS-4 [31] and the cysteine-rich domain of
ADAMTS-5 [29]. Other studies have suggested that KS might have a
role in modulating ADAMTS activity since cleavage in the aggrecan
interglobular domain (IGD) is increased in the presence of endoge-
nous KS and reduced when KS is removed by treatment with kerata-
nases [56–58]. KS attachment sites in the aggrecan IGD map to amino
acids T352, T357, N368 and T370 [59,60], and are strictly conserved in
humans, cattle, horses, rodents, dogs, sheep, pigs and tree shrews.
Furthermore, KS in the IGD of pig aggrecan has a uniquely under-
sulphated microstructure compared with KS elsewhere on aggrecan
[61], suggesting that this KS might also have a speciﬁc function.
3.1. The lectican family of proteoglycans
The lectican [62] (or hyalectan [2]) subfamily of CS proteoglycans
includes aggrecan, versican, neurocan and brevican (Fig. 3). These
proteoglycans are related by the presence of homologous N-terminal
G1 and C-terminal G3 globular domains, with a centrally-located gly-
cosaminoglycan attachment region. The G1 domain is highly homolo-
gous between the lecticans. It contains an immunoglobulin fold that
mediates lectican binding to the family of small globular link proteins
[63], and two homologous proteoglycan tandem repeat (PTR) motifsresponsible for the high afﬁnity binding to (HA) [64], itself an
unsulphated glycosaminoglycan. The HA-binding properties of lecti-
cans are a deﬁning feature of this family.
The name “lectican” reﬂects the structural homology between the
modular components of the G3 domain, and the selectin family of car-
bohydrate binding molecules, with each domain comprising a C type
lectin, EGF-like and complement regulatory (CRP)-like domains. How-
ever, despite the sequence homology, distinct carbohydrate ligands
for lectican G3 domains have not been reported. Instead the G3 domain
binds tenascins [65,66], ﬁbrillins [67] and ﬁbulins [68,69]. Structural di-
versity amongst lecticans arises through alternative splicing [70–72]
and versican is the best example of an alternative spliced lectican (see
Section 5.3). In addition, alternative splicing of G3 domains can create
functional diversity amongst the lecticans; further diversity occurs
when the G3 domain is lost following ADAMTS cleavage.
Lectican CS chain synthesis is initiated by addition of a xylose resi-
due at Ser-Gly or Gly-Ser dipeptides in the glycosaminoglycan attach-
ment region (Fig. 3). The number of CS chains ranges from 3 chains in
brevican, to 7 chains in neurocan, ~30 chains in the unspliced variant
of versican and as many as 100 chains in full length aggrecan. The gly-
cosaminoglycan chains contribute signiﬁcantly to the functional prop-
erties of the lecticans. For example, aggrecan and versican carry a
large number of CS chains and form large multi-molecular aggregates
by binding to HA. The compact distribution of sulphate groups on CS
chains in lectican aggregates creates a high ﬁxed-charge density that at-
tracts counter ions, and consequently water, creating large hydrody-
namic domains. As a consequence there is a high osmotic swelling
pressure in cartilage that confers load-bearing properties, and visco-
elastic properties in blood vessels that are needed to accommodate
high shear stresses and cyclical forces. Most KS in aggrecan is located
on repeating hexapeptide motifs in the KS-rich region [73,74]. While
these motifs number 23 and 13 in bovine aggrecan and human respec-
tively, there are only 4 repeats in rodents [75]. This hasmadeKSdifﬁcult
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KS-rich region
Epidermal growth factor-like domain
Lectin-like domain
CS chain
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Aggrecan
Versican
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Fig. 3. The domain structure of the lectin family of proteoglycans. The modular domain structure of the lecticans (a) aggrecan, (b) versican, (c) neurocan and (d) brevican are
shown. Black arrows mark the ADAMTS cleavage sites that are conserved between mammalian species. The grey arrow marks an ADAMTS-5 cleavage site in bovine aggrecan
that is poorly conserved.
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does not carry KS [76,77].
3.2. The SLRP family of proteoglycans
The characteristic features of the family of small leucine-rich pro-
teoglycans (SLRPs) include a central core protein comprising tandem,
leucine-rich repeat sequences, ﬂanked by N- and C-terminal cysteine-
containing domains, and core substitution with either CS/DS or KS
glycosaminoglycans. The consensus sequence for the leucine-rich
repeats is LxxLxLxxNxLSxL, where L is leucine, isoleucine or valine,
and S is serine or threonine [78]. A less stringent application of the
consensus sequence rule allows for additional repeats. The CS/DS-
containing SLRPs include the well-characterised molecules decorin
and biglycan, and also epiphycan. Other SLRPs carrying N-linked KS
or polylactosamine (unsulphated KS) chains include ﬁbromodulin,
lumican, keratocan, PRELP, osteoadherin, chondroadherin and osteo-
glycin (reviewed in [2–7]) (Fig. 4).
There is enormous variability within the glycosaminoglycan substitu-
tions on SLRPs, many of which account for the functional heterogeneitywithin this family. For example, the core proteins of decorin and biglycan
are structurally similar with 10–11 leucine-rich repeats, and depending
on the tissue source and age of the sample, either one [79] or two [80]
CS or DS chains of varying length, with variable sulphation and uronic
acid epimerisation [5,81]. Epiphycan has fewer repeats, with an extended
N-terminal sequence carrying CS/DS chains and sulphated tyrosine
residues. Fibromodulin and lumican carry N-linked KS chains within the
leucine-rich repeat regions, and also have N-terminal extensions with
sulphated tyrosine residues. Many of these SLRPs can be found as non-
glycanated forms that accumulate with age [82–85]. Interestingly, lumi-
can and keratocan carry KS chainswhen they are expressed in the cornea,
where they are thought to have critical roles inmaintaining corneal trans-
parency by precisely modulating collagen ﬁbrillogenesis. However in
other tissues, lumican and keratocan carry polylactosamine or poorly
sulphated KS chains [86].
Decorin and biglycan have well-recognised roles as modulators of
collagen ﬁbrillogenesis ([87] and reviewed in [3,7]), but in addition,
all members of the SLRP family are recognised as modulators of extra-
cellular signalling (reviewed in [2,6,7]). Their portfolio of activities
includes modulating cell proliferation, ﬁbrosis, inﬂammation and
Fig. 4. The domain structure of the SLRP family of proteoglycans. Adapted from [3].
1621H. Stanton et al. / Biochimica et Biophysica Acta 1812 (2011) 1616–1629
1622 H. Stanton et al. / Biochimica et Biophysica Acta 1812 (2011) 1616–1629immunity, cytokine bioactivity, and receptor-binding associated with
signal transduction (reviewed in [2,88,89]). These divergent function-
al properties reﬂect the presence of multiple interacting domains in-
cluding the horseshoe shaped leucine-rich core domain, the highly
charged N-termini of either tyrosine sulphates, glycosaminoglycans
or clusters of charged amino acids, and the centrally-located KS
chains. Many of the SLRP signalling activities were identiﬁed directly
or indirectly from the phenotypes in SLRP-deﬁcient mice (reviewed
in [88]). There are also sites that bind integrins, and heparin binding
domains (reviewed in [4]).
4. Tools for investigating proteoglycan degradation by ADAMTS
enzymes
A number of valuable resources have been developed and used for
the study of proteoglycan degradation by ADAMTS (and other) en-
zymes, including neoepitope antibodies and “cleavage-resistant” pro-
teoglycan substrates. Neoepitope antibodies detect sequences at the
newly-created N- or C-terminus of proteoglycan fragments, but fail
to recognise the same sequence of amino acids present in the undi-
gested parent molecule. Neoepitope antibodies are speciﬁc for the
products of a single proteolytic event, and are therefore unambiguous
markers of enzyme activity. However, they do not distinguish be-
tween enzymes with identical activities. For example, aggrecan neoe-
pitope antibodies do not distinguish between the activities of
ADAMTS-4, ADAMTS-5 and other potential aggrecanases, but they
readily distinguish ADAMTS-cleaved fragments from fragments
cleaved by matrix metalloproteinases [90]. The neoepitope antibody
speciﬁc for the 374ARGS N-terminal sequence on an aggrecan frag-
ment [91] was instrumental in tracking the enzyme activity that led
to the discovery of ADAMTS-4 and -5 as the aggrecan-degrading en-
zymes [4,92,93]. Subsequently, neoepitope antibodies facilitated the
discovery of a third cartilage aggrecanase in Adamts-4/-5-double deﬁ-
cient mice [94]. Using a similar approach, the development of neoepi-
tope antibodies to brevican [95] and versican [96] have helped
identify ADAMTS enzymes as the proteinases responsible for cleaving
these proteoglycans in vivo.
ADAMTS-resistant substrates have also been developed as tools to
distinguish the activities of ADAMTS and MMP proteinases in vitro
[97] and to conﬁrm a biological role for ADAMTS activity in cartilage
in vivo [98]. In these studies amino acids ﬂanking the ADAMTS cleav-
age site in aggrecan were changed from TEGE373↓374ARGS to
TEGE373↓374NVYS. The same strategy, changing amino acids ﬂanking
the ADAMTS cleavage site in brevican from TESE395↓396SRGA to
TESE395↓396NVYA has been used to successfully block ADAMTS cleav-
age of brevican [99] and reveal that brevican processing by ADAMTS
enzymes is essential for cell motility [100] and glioma cell invasion
[99].
Neoepitope antibodies have also been raised against the N-termi-
nal sequence of PC-activated ADAMTS-4 or ADAMTS-5 enzymes
[101,102]. Unlike the aggrecan neoepitopes that do not distinguish
between the products of ADAMTS-4 and -5 activity, the ADAMTS
neoepitope antibodies detect the enzymes directly, and readily distin-
guish between them. For example, anti-213FASLS antibodies recognis-
ing active ADAMTS-4 have been used to immunolocalise ADAMTS-4
protein in the tibial growth plate of young rats [101].
5. ADAMTS cleavage of proteoglycans in development, disease and
tissue remodelling
There are several ﬁelds of research for which a signiﬁcant body of
literature has developed describing ADAMTS involvement in proteo-
glycan degradation. We discuss these developments in the sections
below, focusing on the proteoglycan cleavage sites and the biological
consequences of the cleavage.5.1. ADAMTS cleavage of proteoglycans in cartilage and tendon
The functional properties of cartilage and tendon are dependent
on a number of proteoglycans. Aggrecan, versican and most members
of the SLRP family are present in one or both of cartilage and tendons.
ADAMTS-4 and -5 have key roles in proteoglycan processing in carti-
lage, and studies in vitro indicate that they have a similarly important
role in degrading tendon proteoglycans.
Aggrecan is the archetypal lectican, named for its ability to form
multimolecular aggregates. It is heavily substituted with CS chains
that attract water, enabling cartilage and tendon to resist compres-
sive and shear forces. In tendon aggrecan has the additional role of re-
ducing the friction between adjacent collagen ﬁbres. Aggrecan is
highly sensitive to proteolysis between the G1 and G2 globular do-
mains, in a region comprising a linear sequence of ~150 amino acids
called the IGD. Proteolysis in the IGD releases the entire CS-rich re-
gion essential for the biomechanical properties of aggrecan, and is
therefore the most detrimental for function. ADAMTS enzymes with
aggrecanase activity cleave at the TEGE373↓374ARGS bond in the IGD
(Fig. 3); this signature activity of the aggrecanases is widely reported
in humans and in animals, in vitro and in vivo, in cartilage and tendon.
However, cleavage at TEGE373↓374ARGS is the less-preferred action of
these enzymes, at least in cartilage. Studies with bovine cartilage aggre-
can have shown that recombinant ADAMTS-4 and -5 preferentially
cleave aggrecan in the CS-2 domain [103,104]. The two most preferred
cleavage sites in bovine cartilage aggrecan are at KEEE1667↓1668GLGS,
followed by GELE1480↓1481GRGT. Thereafter, cleavage occurs at
TEGE373↓374ARGS in the IGD and at TAQE1771↓1772AGEG and
VSQE1871↓1872LGQR in the CS-2 domain (Fig. 3). In cytokine-stimulated
mouse cartilage, cleavage at FREEE1467↓1468GLGS precedes cleavage at
SELE1279↓1280GRGT and FREEE1467 fragments are subsequently con-
verted to SELE1279 fragments by ADAMTS enzymes in cartilage explant
cultures [105]. Whether a similar sequence of ADAMTS cleavage events
occurs in tendon has yet to be determined. Finally, an additional cleav-
age by ADAMTS-5 occurs in bovine aggrecan in the CS-2 domain just
prior to G3, at RPAE2047↓2048ARLE [106]. Unlike the other well-charac-
terised ADAMTS cleavage sites in aggrecan, the sequences surrounding
the E2047↓2048A site are poorly conserved between species.
Recent studies comparing experimental arthritis in wildtype and
Adamts-deﬁcient mice have revealed that ADAMTS-5 is the principal
aggrecan-degrading enzyme in mouse cartilage [107,108]. These
studies showed that ablation of ADAMTS-5 activity blocked cleavage
in the aggrecan IGD and substantially reduced the loss of aggrecan
from femorotibial cartilage. ADAMTS-4 was eliminated as the primary
aggrecanase in the mouse, however it is unclear whether ADAMTS-4
or -5 is the main aggrecanase in human arthritis [109,110]. Targeted
knockdown of ADAMTS-4 and ADAMTS-5 in human cartilage ex-
plants has suggested that both enzymes might have roles in human
arthritic disease [111].
ADAMTS cleavage in the aggrecan CS-rich region (Fig. 3) is
thought to be less detrimental for the weight-bearing properties of
cartilage, since most aggrecan in adult [112] and embryonic [113] car-
tilage lacks the G3 domain and varying portions of the CS-rich region.
These ﬁnding suggest that there is early and ongoing processing of
aggrecan from the C-terminus. In mice, the FREEE1467 neoepitope is
detected in articular and growth plate cartilage from an early age
(Rogerson et al., unpublished), further suggesting that ADAMTS en-
zymes have a role in C-terminal processing of aggrecan. The complete
absence in any animal species [94,105,114–118] of a large aggrecan
fragment comprising both an intact G3 domain and an ADAMTS-de-
rived 374ARGS N-terminus, is further evidence that C-terminal pro-
cessing precedes proteolysis in the IGD. However, it is not clear
which ADAMTS enzyme might be responsible for C-terminal proces-
sing. If C-terminal processing is indeed required for aggrecan turn-
over under baseline conditions, and also as a prerequisite for
accelerated turnover, and if C-terminal processing is mediated by
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in ADAMTS-4 and/or -5 activity have no defects in endochondral bone
formation [94,107,108,119,120]. It is possible that the activity of a
third in vivo aggrecanase, detected in Adamts-4/-5 double-deﬁcient
mice [110] could be the homeostatic aggrecanase.
Aggrecanase activity is more apparent in tendon than cartilage,
since 65% of total aggrecan isolated from bovine tensional tendon
lacks the G1 domain [121]; moreover, aggrecanase-generated aggre-
can fragments are found in cultured tendon explants [121,122]. It is
unclear which aggrecanases are active in tendon, however it is
worth noting that aggrecan fragments with the 374ARGS N-terminus
are found in unstimulated explants of compressed and tensional ten-
don, and the levels of these fragments do not appear to be regulated
by catabolic or anabolic agents, suggesting constitutive ADAMTS ac-
tivity [122,123]. Although this is similar to human and mouse synovi-
al ﬁbroblasts that constitutively express ADAMTS-4 and -5 [124,125],
it is in marked contrast to the situation in cartilage explant cultures,
where the aggrecanases are mostly regulated by catabolic cytokines
(reviewed in [126]). This raises the point that regulation of ADAMTS
expression can be both inducible and constitutive, depending on the
species, cell type or experimental conditions (reviewed in [126]).
Overall, aggrecanolysis in cartilage [127] and tendon [128] is pro-
posed to involve aggrecanase-mediated degradation of proteogly-
cans, as wells as depolymerisation of HA, and MMP-mediated
destruction of the collagen II network.
The SLRPs biglycan, decorin, ﬁbromodulin and keratocan are also
substrates for ADAMTS enzymes in vitro [29–31,129–131]. In solution
phase, bovine ﬁbromodulin is cleaved at a single site (Y44↓45A) by re-
combinant ADAMTS-4 and ADAMTS-5, generating a fragment ap-
proximately 5–10 kDa smaller than the full-length protein
[29,31,132]. This same site is cleaved by MMP-13 [132]. When
human articular cartilage was digested, ADAMTS-4 but not
ADAMTS-5 cleaved ﬁbromodulin, and the latter was a more efﬁcient
aggrecanase [130]. Biglycan and decorin are both cleaved by recombi-
nant ADAMTS enzymes in vitro [29,31,129]. There is a single cleavage
site in the ﬁfth leucine-rich repeat of biglycan at the N149↓150C bond,
which is recognised by ADAMTS-4 (but is distinct from the MMP-13
cleavage site) [133]. Biglycan fragments from cleavage at this site
are present in cartilage from osteo- and rheumatoid arthritis patients
[129]. There is some disparity in the literature about whether
ADAMTS-4 or ADAMTS-5 is more active against biglycan [29,129];
Melching et al. reported more complete proteolysis of biglycan by
ADAMTS-4, whereas Gendron et al. suggested that ADAMTS-5 has su-
perior activity. Similarly, Melching and co-authors reported that dec-
orin is not cleaved by either enzyme, whereas Gendron et al. found
activity (albeit weak) with ADAMTS-4 and to a lesser extent
ADAMTS-5. Keratocan was discovered in tendon relatively recently
[128] and ADAMTS-4 and -5 digest this proteoglycan in bovine ten-
don [123]. There is the suggestion that ADAMTS-4may be more active
against keratocan in compressed regions of tendon, compared with
ADAMTS-5 which is more active in tensional tendon. Whether these
preferences are associated with differences in keratocan glycosylation
[128], or whether other substrates such as aggrecan compete for the
enzymes in the two areas of tendon is unclear.
Despite the apparent activity of ADAMTS-4 and -5 enzymes
against biglycan, ﬁbromodulin, and decorin, the acute increase in
their expression and activity in cartilage following stimulation with
catabolic cytokines [130,134] did not increase their cleavage of
SLRPs. Rather, active degradation of SLRPs correlated with MMP activ-
ity in cartilage cultures [2,130]. Other studies characterising degrada-
tion products in cultured explants of bovine deep ﬂexor tendon found
that despite the abundant release of ADAMTS-derived aggrecan frag-
ments, the versican fragments released from these same cultures
were not produced by ADAMTS activity [121]. It is unclear why
ADAMTS activity does not result in proteolysis of SLRPs or versican
in these two experimental scenarios when they do so in solutionphase. It is also not clear whether ADAMTS activity against SLRPS in
cartilage, or ADAMTS activity against SLRPs and lecticans in tendon,
is indeed pathological. Since SLRPs protect collagen ﬁbrils from colla-
genase cleavage [135], it is possible that ADAMTS degradation of
SLRPs could adversely affect the stability of the collagenous network
and ﬁbril cross-linking, with a concomitant negative impact on mate-
rial properties. On the other hand, since SLRP fragments are readily
generated in explant cultures in the absence of catabolic stimuli, an
alternative possibility is that ADAMTS enzymes might be required
for the normal function of SLRPs in cartilage and tendon.5.2. ADAMTS cleavage of brevican in glioma
Brevican (also termed BEHAB) is a lectican speciﬁc to the central
nervous system. Brevican has several secreted isoforms, including
an isoform that is decorated with 1–3 CS chains and an isoform that
is non-glycosylated. A third isoform that is membrane-bound via a
GPI anchor results from alternative splicing and lacks the typical lec-
tican C-terminus (reviewed in [136]).
Brevican mRNA expression in the brain is spatially and temporally
controlled and peak expression is co-incident with periods of glial cell
motility, such as in the developing brain during gliogenesis, and fol-
lowing experimentally-induced brain injury [137]. A dramatic in-
crease in the expression of brevican mRNA is also a hallmark of
human primary brain tumours [138]. These tumours are highly inva-
sive, are difﬁcult to surgically resect and resistant to conventional
therapies. Signiﬁcantly, brevican expression is very low in tumours
of non-glial origin and in normal human brain [138].
Brevican is processed by ADAMTS enzymes at a single site at the
E395↓396S bond, within the central domain of the core protein
[95,139]. This site is distinct from the main MMP cleavage site that
is 35 amino acids upstream [140]. ADAMTS cleavage of brevican gen-
erates two fragments of 50 kDa and 90 kDa which have long been as-
sociated with brevican's pathological properties [136]. ADAMTS-4
and -5, but not ADAMTS-1, generate these fragments in culture
[95,141]. Of the three, only ADAMTS-5 mRNA is overexpressed in
human glioma tissues in comparison with normal brain [141]. How-
ever, higher levels of expression alone do not necessarily indict
ADAMTS-5 as the principle brevicanase in glioma because other
pre- and post-translational mechanisms modulate ADAMTS activity
(reviewed in (64)). What is clear is that cleavage at the E395↓396S
site is a necessary step in glioma cell invasion, as seen in a study
that mutated the sequence E395↓396SRGA to E395↓396NVYA, rendering
it resistant to ADAMTS cleavage [99]. When CNS-1 cells stably expres-
sing the mutant BrevicanNVY were implanted in rat brain, the tumours
formed were no different in size to control tumours, nor was there
any difference in survival endpoint from control animals. In contrast,
animals implanted with CNS-1 cells overexpressing normal brevican
formed tumours that were larger, more diffuse and more inﬁltrative
than those measured in BrevicanNVY or control animals and the sur-
vival endpoint was signiﬁcantly earlier [99].
Brevican has traditionally been described as a chemorepulsant,
acting to limit cell motility and plasticity in the adult central nervous
system [137], so it is somewhat counterintuitive to ﬁnd that brevican
promotes glioma cell motility. The reason appears to lie in the expres-
sion of altered isoforms of brevican. There are over-sialylated and
non-glycosylated isoforms of brevican that are tumour-speciﬁc; the
non-glycosylated form is the major isoform in high-grade human gli-
omas [142]. Furthermore, conditions that favour ADAMTS-cleavage
also promote glioma cell movement, activation of the EGF receptor,
expression of cell-adhesion molecules and secretion and accumula-
tion of ﬁbronectin on the cell surface [100]. Thus, reagents that target
the tumour-speciﬁc isoforms of brevican, or inhibit ADAMTS-cleavage
of brevican have potential as complementary therapies for primary
brain tumours. Inhibiting ADAMTS cleavage of brevican might slow
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crease the efﬁcacy of surgical, radiation or chemotherapies.
5.3. ADAMTS cleavage of versican in vascular disease, angiogenesis,
ovulation and tissue morphogenesis
Versican is the principal lectican in many tissues where it provides
a loose and highly hydrated matrix. It has a typical lectican composi-
tion (Fig. 3) and considerable heterogeneity is provided by alternative
splicing of the GAGα and GAGß domains. Further heterogeneity is
conferred by the size and composition of the attached CS chains.
Versican has roles in cell adhesion, proliferation, migration and extra-
cellular matrix assembly [143].
Soluble versican V1 is degraded by ADAMTS-1, -4, -5, -9 and -20 at
the E441↓442A bond [21,34,96,144,145] in the GAGβ domain. Cleavage
at this site creates the G1-DPEAAE441 fragment and an anti-DPEAAE
neoepitope antibody has been instrumental in mapping versican deg-
radation by ADAMTS enzymes in a number of tissues, including nor-
mal and atherosclerotic human aorta [96]. The equivalent ADAMTS
cleavage site in the GAGα domain of V0 is E1428↓1429A and the frag-
ment G1-DPEAAE1428 has also been found in low abundance in ex-
tracts of human aorta [96]. ADAMTS-4 cleaves the GAGα domain at
E405↓406Q in the versican V2 variant and cleavage of human brain
V2 at this site generates glial HA binding protein [146]. These
ADAMTS cleavage sites in the GAGα and GAGβ domains are distinct
from the MMP and plasmin cleavage sites [147].
5.3.1. Vascular disease
All isoforms of versican are found in blood vessel walls
[96,148,149]. Versican is prominent in the intima and adventitia
where it forms stable complexes with hyaluronan and link protein,
to provide a hydrated viscoelastic matrix. Immunohistochemical
studies have shown that versican accumulates in the intima in vascu-
lar lesions including atherosclerotic plaques, restenotic lesions, le-
sions associated with graft repair and aneurysmal lesions [150]. It is
present in early atherosclerotic intimal thickenings where it contrib-
utes to the expansion of the intima by attracting water. Versican is
also present in advanced atherosclerotic lesions, at the edges of the
necrotic core, where it retains lipids by binding low density lipopro-
tein. Multiple low density lipoprotein particles can bind to a single
CS chain on versican (or other CS-bearing proteoglycans), thus the
elongated CS chains seen in vascular injury contributes to lipid accu-
mulation (reviewed in [151,152]). Versican CS chains also bind cell
adhesion molecules and chemokines [153,154] and versican-HA com-
plexes present at the plaque:thrombus interface in atherosclerotic
plaques suggest a role for versican in thrombosis [155]. These com-
plexes are found in the transitional ECM formed following injury to
blood vessels, and are thought to contribute to intimal hyperplasia
by permitting smooth muscle cell (SMC) migration and proliferation
[156]. Over time, the intimal hyperplasia associated with balloon or
stent-mediated injuries regress. Importantly, this is associated with
the loss of versican [157–159].
What roles then, for ADAMTS cleavage of versican in vascular pa-
thologies? There is mounting speculation that versican fragmentation
could promote intimal regression [147,152]. Therapies aimed at pre-
venting restenosis following vascular reconstruction have traditional-
ly focused on inhibiting intimal hyperplasia, but therapies aimed at
promoting intimal atrophy may also have merit, particularly once re-
stenosis is evident [147]. A promising study by Kenagy et al., has
shown that high blood ﬂow/high shear conditions through aortic
iliac grafts in baboons is associated with neointimal atrophy [160],
SMC death and versican degradation [161]. In this model system,
ADAMTS-4 mRNA levels were elevated in the neointima of the grafts,
whereas the mRNA levels for ADAMTS-1, -5, -8, -9, -15 and -20 were
unchanged [161]. Furthermore, ADAMTS-4 generated the DPEAEE
neoepitope in this system, whereas ADAMTS-1, -5, -8, -9, -15 and-20 did not [161]. Moreover, the addition of Fas ligand to aortic SMC
cultures increased ADAMTS-4mRNA and cell-death by approximately
5-fold, suggesting a causal relationship between ADAMTS-4 cleavage
of versican, cell death and tissue atrophy in aortic-iliac grafts under
these conditions [161].
Jonsson-Rylander et al. [162] have shown that ADAMTS-1 protein
is upregulated in intimal tissue when plaque is present. ADAMTS-1 is
expressed by migrating and proliferating primary aortic SMC in vitro,
and contributes to intimal thickening in a carotid artery ﬂow cessa-
tion model [162]. Others have shown that ADAMTS-4 and -8 are pre-
sent in advanced atherosclerotic plaques and that ADAMTS-4 mRNA
is induced during lesion development in a mouse model of athero-
sclerosis [163]. Given the many, and diverse roles of versican in vas-
cular disease, and the presence of the ADAMTS enzymes, the
likelihood that ADAMTS cleavage of versican contributes to vascular
pathology is high. It will be interesting to watch this area of research
unfold.
5.3.2. Angiogenesis
Pathological angiogenesis is a fundamental process in tumour ma-
lignancy and chronic inﬂammatory diseases. The initial step involves
breakdown of the venular basement membrane; subsequent remo-
delling permits vascular expansion, and the formation of highly ab-
normal and hyperpermeable “mother” vessels (MVs). Vascular
endothelial growth factor/vascular permeability factor (VEGF-A/
VPF) is a major contributor to this process. Pathological angiogenesis
can be modelled in vivo by injecting an adenoviral vector expressing
VEGF164 into nudemice. Using this model, Fu et al. [164] have demon-
strated recently that versican in the basement membrane is degraded
early in the course of pathological angiogenesis, as evidenced by the
loss of versican staining and the appearance of the DPEAAE epitope,
localised to MV endothelial cells. ADAMTS-1 protein increased
in vivo concomitant with MV formation. As the MV formed daughter
vessels, strong staining for versican reappeared. The data suggest a
role for ADAMTS-mediated remodelling of versican during patholog-
ical angiogenesis.
5.3.3. Ovulation
ADAMTS activity against proteoglycans often leads to pathology,
as discussed above. However, there are other situations in which
ADAMTS cleavage of proteoglycans is part of normal physiology,
and in these situations, ablation of ADAMTS activity can have detri-
mental effects in vivo. One example is the release of mature oocytes
from the ovarian follicle during ovulation. Proteoglycans are impor-
tant components of the ovarian follicle and follicular ﬂuid [165]. In
particular, versican is selectively localised to the expanding follicle
[166] where it is thought to promote the inﬂux of ﬂuids and to inter-
act with hyaluronan to help stabilise and support this rapidly expand-
ing matrix. ADAMTS-1 also accumulates in the expanding follicle
matrix where its expression is increased 10-fold [167].
Proteinases, including several ADAMTS enzymes, are expressed in
the mammalian ovary (reviewed in [168]), but to date only ADAMTS-1
is known to have an essential role in normal ovulation, based on the
phenotype of the Adamts-1 null mouse [169,170]; Adamts-1 null fe-
males are sub-fertile. They have a normal eostrous cycle but impaired
oocyte release, with a signiﬁcant proportion of oocytes retained within
the follicle after ovulation. Thus, theAdamts-1null femalemousepheno-
copies the ovulatory failure seen in the progesterone receptor null
mouse [171]. This is not surprising, given that one feature of the proges-
terone receptor null mouse is its inability to induce ADAMTS-1 [172].
Importantly, a positive correlation between Adamts-1 gene expression
and ADAMTS-1 activity in the ovarian follicle is conﬁrmed by the pres-
ence of the versican DPEAAE neoepitope [167]. Russell et al. have there-
fore concluded that one function of ADAMTS-1 during ovulation is to
cleave versican, and that failure to do so in either the Adamts-1 null
mouse, or the progesterone receptor null mouse, causes impaired
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tures of the Adamts-1 null mouse include follicular dysmorphogenesis,
delayed development of the ovarian lymphatic system and impaired or-
ganisation of the medullary vascular network of the ovary [173,174].5.3.4. Tissue morphogenesis
Versican is widely expressed in embryonic tissues where it is often
co-expressed with ADAMTS enzymes. ADAMTS cleavage of versican is
thought to be essential in numerous developmental processes, many
of which have been elucidated in Adamts-deﬁcient mice by associa-
tion, or with the anti-DPEAAE neoepitope antibody. For example,
bone is synthesised during skeletal development and fracture healing,
initially as woven bone which is comparatively weak and less ordered
than the more mature lamellar bone by which it is eventually
replaced. During the transition from woven bone to lamellar bone
in development of the rat mandible and hind limbs, there is a con-
comitant transition in the composition of the bone matrix from one
rich in versican and ADAMTS-1, -4, -5, to a mature bone matrix that
has a decreased content of versican and ADAMTS-proteinases [175].
The authors of this study propose that versicanolysis by ADAMTS pro-
teinases is associated with bone maturation.
Syndactyly, or webbing of toes and ﬁngers, occurs normally in foe-
tal development but is usually lost by birth due to apoptosis and pro-
teolysis of the interdigital web. Recent studies in mice with
compound mutations in the genes for Adamts-5, Adamts-9 and
Adamts-20 suggest that the catalytic activity of two or more ADAMTS
enzymes against versican at the E441↓442A site is essential to allow re-
gression of the interdigital web in mouse paws, possibly by reducing
the threshold for BMP-induced apoptosis needed to ensure web
regression [176].
Cleft palate describes the failure of the lateral palatine processes to
fuse, and therefore close. As a consequence, the nasal cavity and the
mouth are directly connected rather than separated by the roof of
the mouth. Versican is abundant in palatal shelf mesenchyme and in
mice, combined loss of ADAMTS-9 and -20 activity in the vascular en-
dothelium and the palate mesenchyme, respectively, causes cleft pal-
ate [177]. The defects in versican processing were detected by a loss
of DPEAAE immunoreactivity [177].
ADAMTS-20 is also involved in the development of skin pigmenta-
tion. Adamts-20mutant mice have a distinctive coat with a white belt
in the lumbar region. Versican and DPEAAE epitopes are enriched in
skin, and one of the (several) likely mechanisms by which ADAMTS-
20 contributes to pigmentation is by remodelling versican in the
ECM surrounding melanoblasts in the embryo [145]. Silver et al.
showed that DPEAAE immunoreactivity, but not total versican immu-
noreactivity, is reduced in the skin of Adamts-20 mutant mice com-
pared with wildtypes. ADAMTS-5 also has a role in proteoglycan
remodelling in adult skin [178]. In a model of excisional wound heal-
ing, versican and aggrecan accumulate in the skin of Adamts-5−/−
mice during the period of wound contraction, compared with wild-
type mice. In this model, the over-abundance of versican and its ca-
tabolites resolves as the wound repairs suggesting that versican is
degraded by a proteinase other that ADAMTS-5. However, pericellular
aggrecan is retained in the Adamts-5−/− mouse dermis. The authors
propose that aggrecan retention in the Adamts-5−/− mice delays
wound healing by preventing ﬁbroblastic cells from maturing into
contractile ﬁbroblasts [178].
During development of synovial joints, a proportion of cells within
the developing limb form an interzone of non-chondrogenic cells that
separates the future cartilage elements. As cavitation begins to form
the synovial cavity, the interzone cells show strong expression of ver-
sican and secrete high levels of HA. Recently investigators studying
limb development in mice detected increased cleavage of versican
by ADAMTS enzymes in the interzone, via immunodetection of the
DPEAAE neoepitope [179]. This immunoreactivity overlapped withADAMTS-1, but not ADAMTS-4 immunoreactivity, implicating the
former as a key proteinase in joint cavitation. However, there must
be redundancy in this process since joint dysmorphology is not a fea-
ture of the Adamts-1 null mouse.
During foetal cardiac valve development, the provisional proteo-
glycan-rich ECM is replaced by a stratiﬁed ECM that includes collagen
and elastin. Anomalies of the cardiac valve in early development are
marked by persistence of the proteoglycan-rich matrix, suggesting a
failure to resorb the provisional matrix. Adamts-5−/− mice develop
enlarged cardiac valves by late foetal stages and a recent report
showed that these enlarged valves are associated with reduced versi-
can cleavage in the sub-endocardial matrix, seen by decreasing stain-
ing for the DPEAAE epitope [180]. The valve phenotype can be
signiﬁcantly rescued by decreasing the levels of versican in the matrix
via versican heterozygosity for the Vcan gene in the Adamts-5−/−
mouse [180]. These ﬁndings suggest that a lack of versican cleavage
during development of the foetal valve may have a role in future car-
diac valve disease.
A parallel study showed that Adamts-5−/−mice also have a dermal
ﬁbroblast phenotype, marked by reduced versican proteolysis in the
pericellular matrix [181]. This is associated with an altered cell shape
and enhanced contractility in collagen gels, typical of myoﬁbroblasts.
The ﬁbroblast-myoﬁbroblast transition was reversed by heterozygous
expression of the inactive Vcan gene in the Adamts-5−/− mouse,
suggesting that versican turnover by ADAMTS-5 is needed to maintain
dermal ﬁbroblast phenotype.
One mandatory consequence of versicanolysis at the E441↓442A
site, be it a pathological or physiological event, is the formation of a
G1-DPEAAE fragment whose size is dependent on the isoform of the
parent versican molecule. There is continuing intrigue and specula-
tion amongst the research community that this fragment, and other
catalytic fragments of proteoglycan substrates, might have unique bi-
ological properties that are not invested in the parent molecules. In-
deed, recombinant single domains of versican appear to have
bioactivity in cell culture systems [182–184].6. Perspectives
Proteoglycans in extracellular matrices are degraded by ADAMTS
enzymes in many and varied biological situations. Given the extent
of this proteolysis in vivo, the prospect that the products of proteogly-
can proteolysis are signalling molecules that allow cells to monitor
the health and integrity of their extracellular environment is an excit-
ing, albeit not entirely new, consideration. Bioactive fragments of de-
graded matrix can interact with cells or other matrix components to
signal in ways that are distinctly different to their parent precursors.
We envisage that fragment signalling could modulate normal tissue
homeostasis or arise in response to tissue pathology. These catalytic
events can be mapped with neoepitope antibodies and used as poten-
tial biomarkers of destructive or regenerative proteolysis in vivo. Pro-
teoglycan fragments resulting from ADAMTS cleavage could also be
exploited for drug development.Acknowledgements
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